FundingMediWound received €16.5 million in funding from the European Innovation Council to accelerate the development of EscharEx in the DFU indication.
Market ExpansionNexoBrid is expanding into new markets including the US, Japan, and India, and has secured a partnership for promotion in European countries.
Product DevelopmentEscharEx is being developed for enzymatic debridement of chronic wounds in the outpatient setting, representing a potential $2.5 billion market opportunity.